Targeting METTL3 or IGF2BP2 may represent a promising therapeutic strategy, and the analysis of METTL3 and IGF2BP2 expression could be a potential signature for predicting the sensitivity of clinical radiotherapy in HCC. This evidence concerns the gene IGF2BP2 and hepatocellular carcinoma.